Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02749903 · ClinicalTrials.gov registry record · Phase 2
Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
A Phase 2 study of Salivary Cancer, sponsored by Alliance for Clinical Trials in Oncology.
- Active
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 20
- Study locations
NCT02749903 is a Phase 2 study of Salivary Cancer that is active but no longer recruiting, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 46 participants. The trial reports 20 study locations across 2 states.
The verdict
NCT02749903, a Phase 2 study of Salivary Cancer, is active but no longer recruiting, sponsored by Alliance for Clinical Trials in Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will test any good and bad effects of the study drug called enzalutamide. Enzalutamide could shrink the cancer but it could also cause side effects. Researchers hope to learn if the study drug will shrink the cancer by at least 30% compared to its present size, in at least 1 out of 5 patients. Enzalutamide is not FDA approved to treat salivary gland cancer, but it has already been FDA-approved to treat other cancers.
Conditions Studied
Interventions
- DRUG enzalutamide
Study Locations (20)
California
- Kaiser Permanente-Anaheim - Anaheim
- Kaiser Permanente-Baldwin Park - Baldwin Park
- Kaiser Permanente-Bellflower - Bellflower
- Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
- Kaiser Permanente-Fontana - Fontana
- Kaiser Permanente-Irvine - Irvine
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Kaiser Permanente-Cadillac - Los Angeles
- Kaiser Permanente-Ontario - Ontario
- Kaiser Permanente - Panorama City - Panorama City
- Kaiser Permanente-Riverside - Riverside
- Kaiser Permanente-San Diego Mission - San Diego
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2016-09-14 |
| Est. Completion | 2028-07-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02749903
The ClinicalTrials.gov registry entry for NCT02749903 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Salivary Cancer appearing as the primary indexed condition, and to 1 intervention - of which enzalutamide is the first listed.
NCT02749903 reports 20 study locations spanning 2 distinct geographic areas - top geographies include California, Alaska.
Frequently Asked Questions
What is clinical trial NCT02749903 about?
NCT02749903 is a clinical study titled "Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers". This study will test any good and bad effects of the study drug called enzalutamide. Enzalutamide could shrink the cancer but it could also cause side effects. Researchers hope to learn if the study drug will shrink the cancer by at least 30% compared to its present size, in at least 1 out of 5 pati...
What is the current status of trial NCT02749903?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2016-09-14. Estimated completion is 2028-07-05.
What conditions does trial NCT02749903 study?
This clinical trial studies the following conditions: Salivary Cancer.
What interventions are being tested in trial NCT02749903?
The interventions under investigation include: enzalutamide (DRUG).
Who is sponsoring clinical trial NCT02749903?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02749903 being conducted?
This trial has 20 study locations across Alaska, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.